started · updated
Biogen expands pipeline beyond neurology to drive growth
Biogen is working to diversify its business beyond its traditional focus on neurology. During a Wells Fargo conference, Chief Financial Officer Robin Kramer stated that the company is focused on advancing a broader late-stage pipeline and managing expenses to return to growth.
The company currently has 10 Phase III programs, with results expected to begin in the fourth quarter. Biogen is utilizing its ‘Fit for Growth’ initiative to optimize its cost base and redirect investment from its multiple sclerosis portfolio toward newer product launches, such as LEQEMBI, SKYCLARYS, and ZURZUVAE.
Additionally, Biogen has expanded into immunology and nephrology through the acquisition of HI-Bio and the felzartamab asset. Adam Keeney, head of corporate development, noted that the company is prioritizing development opportunities with validated endpoints and clearer regulatory paths.